, a innovator in neuro-scientific regenerative medication, announced today that it’s been issued a patent on its single-blastomere technique. The single-blastomere technology runs on the one-cell biopsy approach very similar to pre-implantation genetic diagnosis , which is trusted in the in vitro fertilization procedure and does not interfere with the embryo’s developmental potential.D., chief scientific officer of Work, stated, This patent issuance represents reputation of the advancement underlying our single-blastomere technology.1 Journal of the American Medical Association. According to Maris, the results are important because they show that genetic sequencing has the potential to greatly help children with malignancy that relapses or does not react to treatment at all. ‘But we still have a long way to go,’ Maris said. Probably the biggest obstacle is that newer drugs often can’t be used for kids because there is no data on the safety and effectiveness for children – – and there are no pediatric scientific trials underway. The current findings derive from 91 pediatric cancer patients at Mott Children’s Hospital who were out of standard treatment plans. Mody’s group analyzed each child’s genetic blueprint, or genome – – including RNA and DNA from their tumors and healthy cells.